Via practica 2/2020

COVID-19, ibuprofén, inhibítory angiotenzín-konvertujúceho enzýmu, sartany

Since the outbreak of the novel coronavirus SARS-CoV-2, the effect of some drugs on the prognosis and course of COVID-19 has been discussed among professionals and the general public. To date, no experimental or clinical studies on the negative effects of ibuprofen, other non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme (ACE) inhibitors, and type I angiotensin receptor blockers (sartans) on the course of COVID-19 are known. Several international health organizations do not recommend changes in the indication of NSAIDs and recommend continuing treatment with ACE inhibitors or sartans in indicated patients regardless of COVID-19.

Keywords: COVID-19, ibuprofen, angiotensin-converting enzyme inhibitors, sartans